Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (9530)	4/5/1999 1:26:00 AM
From: LarryS	Read Replies (1) \| Respond to of 17367

Do the doctors really believe in Neuprex so much that they would fudge rules to get it?? If it turns out as good as we hope, maybe. But from our price I would say most of the medical community doesn't believe Neuprex is that awsome....and certainly not enough to put their reputation and employment on the line. I wish they did, I think our price would be higher. Sure would like to hear some in the medical profession write us saying they were investing in XOMA because a miracle happened in their hospital during the Neuprex trials....

To: Bluegreen who wrote (9530)	4/5/1999 7:06:00 AM
From: Robert K.	Read Replies (1) \| Respond to of 17367

I dare say that the zero deaths hypothesis is possible but unlikely for the mere fact it might be impossible to justify the trial length if so. I have excluded it as a possibility because I dont want to think about it. Regarding magainin, I remember the Discover article. The problem they had with production(I think) was how do you make a peptide that kills bacteria through production in bacteria, without killing the bacteria trying to produce it. The animal method would circumvent that problem. However, I think X has production capabilty anyways. Standard K disclaimers.

To: Bluegreen who wrote (9530)	4/5/1999 11:55:00 AM
From: Andy Mullan	Respond to of 17367

Who is doing antimicrobial peptide work? Micrologix in Vancouver has made this the focus of their efforts. I'd be interested in your comments. mbiotech.com

To: Bluegreen who wrote (9530)	4/5/1999 4:36:00 PM
From: Cacaito	Read Replies (1) \| Respond to of 17367

Bluegreen, I do not have any further ideas for "possible" lower mortality, a very low mortality in Bpi group could be one The zero option is too exuberant for serious money talk, I invest the old way with my money (got to work hard for it) and not a chance of getting a florless conversion to protect my shorting. I want the accruals to keep going for a total of 600 to 800 subjects, to ensure bpi will be proven effective or not without doubts. Cloning the Dolly way was conceptualized 50 years ago, what was needed was a vry small driller (it seems they got one) and gently placing DNA in an empty ovule (via the same hole that emptied it out to begin with) and gently enough to get it going. Very clever to use the ovule own mechanisms (nature ready) to do the job. The cloning that is tough is to actually do it the way Geron is trying to, getting stem cells to clone either a full organ or even certain tissues, forget a full animal (men/women included) this way will be very useful, and troubleful in the ethics field. So far they are happy spending $ millions multiplying stem cells 25 times. One need couple of trillions multiplication.